semaglutide clinical trials near me American Federation of Medical Research | Could one medication change the future of obesity treatment? Landmark found that consistently outperformed A new clinical trial supported

Previous studies reported that the administration of the GLP-1R agonist exendin-4 (25 nmol/kg, twice daily) inhibits learning and memory formation through the suppression of synaptic plasticity in the hippocampus of a high fat diet mouse model (Gault et al., 2010

That said, while the therapeutic potential is massive, the clinical trials for newer peptides are still in early phases

Compared to liraglutide, which requires daily injections and typically results in more modest weight loss, semaglutide offers a more convenient weekly dosing schedule and greater reductions in body weight

pmid:31991717 4

So read the label, and steer clear of additives containing stimulants

Contrave Naltrexone HCI/bupropion HCI 8mg/90mg extended-release tablets Am I a good candidate for GLP-1s